Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules ...

Overall, the study found that tirzepatide was more effective at helping participants lose weight. About 82% of participants taking tirzepatide experienced 5% or greater weight loss.

Diabetes drug Mounjaro helped people lose 16% of weight, study finds Two trials have now found tirzepatide, sold under the brand name Mounjaro as a diabetes treatment, to be effective for weight loss.

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

Tirzepatide may be more effective than semaglutide in helping people who have obesity or overweight lose weight, results from a recent study suggest.